SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018....

Biosimilars 2017 draws from European experience to unveil new market access and commercialisation strategies for an evolving pharmaceutical landscape

Biosimilar drug manufacturers will no longer need to wait an extra six months after FDA approval to launch their product, following a recent U.S Supreme Court decision. The ruling which allows biosimilar drugs to enter the market faster is expected to save patients and the U.S. health system billions of dollars....

FDA Division of Anti-Infective Products Director, Sumathi Nambair, due to Present at Superbugs & Superdrugs 2017

SMi Group are thrilled to have industry expert Sumathi Nambair, provide regulatory and compliance updates on FDA legislation in antibacterial drug development at the 19^th annual 2017 Superbugs & Superdrugs show, returning to Central London on 20^th and 21^st March.

SMi Group are thrilled to have Jeffrey Ulmer, Head of Preclinical Research & Development from GSK, present a keynote at RNA Therapeutics 2017 when it returns to Central London next February.

With a focus on mRNA vaccines, the talk will delve further into key topics surrounding immune responses, animal models, platform technology and rapid response to emerging infectious diseases. In the run-up to his address, Dr Ulmer said: “RNA therapeutics, including recent exciting advancements in RNA-based vaccines, have the potential to be game-changing technologies....

Industry expert Dr John Rex will be presenting a special keynote address on the global crisis of antibiotic resistance at SMi’s Superbugs & Superdrugs congress this fall.

The industry meeting set to take place on Nov 14^th and 15^th in Iselin, New Jersey, will gather a global audience of scientific leaders, funding bodies and drug development specialists, providing a focal point to discuss funding opportunities and clinical advancements in drug discovery....

SMi Groups 5th annual Cancer Vaccines conference returns to London this autumn to discuss new breakthroughs in cancer vaccine development.

SMi Group is thrilled to present the 5th annual Cancer Vaccines conference, taking place on 21st & 22nd September 2016 in Central London, UK. Aimed at an audience of senior scientists and oncology specialists involved in targeted vaccines and drug research, Cancer Vaccines 2016 will aim to provide a perfect platform to discuss pioneering clinical developments and the next generation of cancer immunotherapy.

Interview released with US Federal Agency, Biomedical Advanced Research and Development Authority (BARDA), in the run up to SMi’s 18^th annual show on antimicrobial resistance.

SMi’s 18th annual conference on “Superbugs & Superdrugs” returns to London this March and is thrilled to have Dr. Christopher Houchens, Project Manager of BARDA's Anti-Infective Programme, as one of the keynote speakers for 2016. It was announced last September that the US Government would provide the federal agency, BARDA, which works on national preparedness for chemical and biological threats, funding of $96 million to explore new therapies

Have superbugs breached the last line of antibiotic defences for the first time? Industry gathers next March to collaborate on tackling antimicrobial resistance

With a focus on pushing financial and collaborative incentives to accelerate clinical success of antibiotic drugs, the agenda for SMi’s 18th annual summit on Superbugs & Superdrugs will spotlight on models for successful partnerships, progressive R&D, strengthening the antibiotic pipeline and pioneering approaches to "smart" antibiotics.

SMi Group reports: 7^th annual Pre-Filled-Syringes Conference will be taking place in London, on the 28-29 January 2015.

The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. This field is evolving in response to changing patient populations, new classes of powerful therapeutic drugs and healthcare administration initiatives....

SMi Group reports: Biosimilars & Biobetters Conference will taking place in London on 29th & 30th September 2014. 3-day event, over 16 innovative presentations, 2 half-day workshops, hours of networking

Building unto the success of last year, Biosimilars & Biobetters 2014 will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market. The agenda aims to bring together pharma, biotech and legal experts explaining the advantages and disadvantages within this growing market, looking at case studies from those who are developing and distributing follow on...

Industry Leaders will meet in Iselin, New Jersey, USA to discuss current and emerging trends within the industry

The importance of pre-filled syringes and injection devices have never been more pertinent, especially in the US. The challenges of finding a delivery method with patient centric design that avoids leaching, requires swift and decisive decisions early in the development process to avoid unnecessary costs and delays in development. The SMi Group announces its Pre-Filled Syringes America Conference will be taking place in ....

SMi’s event promises to bring together world-renowned experts to present the hottest topics and key challenges faced within the Generics industry today.

With presentations and interactive panel discussions, the event will provide attendees with the latest updates on increasing profitability in a highly competitive market, how to overcome some of the IP issues faced when challenging patents and a detailed look at the pricing pressures surrounding an already saturated marketplace...

COPD is a life threatening disease which negatively affects normal breathing. It is characterised by persistent blockage of air flow to the lungs. COPD encapsulates chronic bronchitis and emphysema. The most common cause of patients getting COPD is tobacco smoke. This is either from smoking or from second hand smoke

SMi is excited to announce its much anticipated Biomarkers Summit taking place in London on Monday 31st January and Tuesday 1st February, 2011.  Offering an intensive two day program designed to maximise your time out of the office. The dual track program promises to be the largest and most comprehensive Biomarkers event run by SMi to date. Sponsored by Caprotec, Genstruct & RBM